ORIGINAL INVESTIGATION. Use of Urinary Albumin Excretion and Estimated Glomerular Filtration Rate

Size: px
Start display at page:

Download "ORIGINAL INVESTIGATION. Use of Urinary Albumin Excretion and Estimated Glomerular Filtration Rate"

Transcription

1 ORIGINAL INVESTIGATION Definition of Kidney Dysfunction as a Cardiovascular Risk Factor Use of Urinary Albumin Excretion and Estimated Glomerular Filtration Rate Massimo Cirillo, MD; Maria Paola Lanti, MD; Alessandro Menotti, MD; Martino Laurenzi, MD; Mario Mancini, MD; Alberto Zanchetti, MD; Natale G. De Santo, MD Background: Urinary albumin excretion (UAE) and estimated glomerular filtration rate (egfr) have been used separately to provide information about cardiovascular risk. We analyzed whether UAE and egfr used together provide complementary information. Methods: We analyzed UAE, egfr, cardiovascular risk factors, and incidence of cardiovascular disease in 1665 men and women of the Gubbio Population Study (aged years). We designated UAE in the highest decile as high ( 18.6 µg/min in men and 15.7 µg/min in women) and egfr in the lowest decile as low ( ml/min/1.73 m 2 in men and ml/min/1.73 m 2 in women). Results: Kidney dysfunction defined using both markers was more frequent than using 1 marker (UAE alone or egfr alone) (P.001) because high UAE and low egfr clustered in different individuals and were weakly associated with each other (P=.12). The hazard ratio (HR) for incident cardiovascular disease was elevated for both markers, independently of each other (HR for high UAE, 2.15; 95% confidence interval [CI], ; HR for low egfr, 2.14; 95% CI, ). Kidney dysfunction defined by both markers predicted cardiovascular disease independently of sex, age, hypertension, hypercholesterolemia, smoking, diabetes mellitus, prior cardiovascular disease, left ventricular hypertrophy, and obesity (HR, 1.50; 95% CI, ). The discriminant power of dysfunction defined by both markers was statistically significant (area under the receiver operating characteristic curve, [P=.02]) and slightly higher than what was found with 1 marker of diabetes mellitus, prior cardiovascular disease, left ventricular hypertrophy, and obesity. Conclusions: High UAE and low egfr provide complementary information in defining kidney dysfunction because they cluster in different individuals. Concomitant evaluation of both markers should be considered to adequately assess kidney dysfunction and cardiovascular risk. Arch Intern Med. 2008;168(6): Author Affiliations: Unit of Nephrology, Second University of Naples (Drs Cirillo and De Santo), and Unit of Internal Medicine, Federico II University (Dr Mancini), Naples; Association for Cardiac Research, Rome (Drs Lanti and Menotti); Center for Preventive Medicine, Gubbio (Dr Laurenzi); and Centro Fisiologia Clinica e Ipertensione, Istituto Auxologico Italiano, Ospedale Maggiore, University of Milan, Milan (Dr Zanchetti), Italy. SEVERAL GUIDELINES INDICATE kidney dysfunction as a cardiovascular risk factor on the basis of data showing a relation with cardiovascular disease for 2 markers of kidney function: urinary albumin excretion (UAE) and glomerular filtration rate (GFR). 1-3 Longitudinal population-based studies support these statements For UAE, cardiovascular risk was elevated in persons with macroalbuminuria 4-6 and microalbuminuria. 7-9 For GFR, cardiovascular risk was elevated in persons with clinically elevated serum creatinine levels and by calculation of the estimated GFR (egfr) To our knowledge, no previous studies have reported complete data on both UAE and egfr. Thus, it is uncertain whether the 2 markers of kidney function provide complementary or overlapping information for cardiovascular risk. This point could be important for understanding the mechanisms linking kidney dysfunction to cardiovascular disease and for practical considerations regarding the optimal workup for the assessment of cardiovascular risk. The main objective of the present population-based study was to investigate prospectively the association with cardiovascular disease of kidney dysfunction defined using 2 markers (high UAE and low egfr) compared with kidney dysfunction defined using a single marker (high UAE alone or low egfr alone, alternatively). METHODS The Gubbio Population Study is an investigation ofapopulationsampleresidinginthecityofgubbio in central Italy. 22 Activities were approved by thelocalinstitutionalcommitteeandincludedan informed consent. Previous studies report information on response rates, responders and nonresponders, similaritiesofthegubbiopopulation to the Italian population, and the timing of examinations Thetargetcohortofthepresent analysisislimitedtoexamineesaged45to64years 617

2 at the examination (hereinafter referred to as the baseline examination) because UAE was measured only for these individuals. 24 The baseline examination included the collection of timed overnight urine samples and morning blood samples under fasting conditions, the administration of questionnaires on cardiovascular disease and treatment, 28 a 12-lead electrocardiogram interpreted according to the Minnesota code, 28 and measurements of anthropometry and blood pressure. Measurements of laboratoryvalueswereperformedbymeansofautomatedproceduresand included levels of urinary albumin (using immunoturbidimetry after ultrafiltration), 24 serum glucose, total and high-density lipoprotein cholesterol, 22,24 and serum creatinine (using a kinetic alkaline picrate assay). 27 The intra-assay error in daily blind duplicates was less than 10% for urinary albumin levels and less than 5% forserumvariables. Trainedphysiciansadministeredquestionnaires and measured blood pressure after a 5-minute rest in the sitting position using mercury sphygmomanometers and cuffs of appropriate size. The mean of the second and third blood pressure measurements was used for analyses. KIDNEY FUNCTION The UAE was expressed in micrograms per minute, not as the ratio of urinary albumin to creatinine levels, to avoid the misclassification of a high ratio secondary to low urinary creatinine levels. 26 The egfr was calculated by the following abbreviated equation of the Modification Diet in Renal Disease Study (MDRD) 2 : 186 Serum Creatinine Level Age ( for Women). The ethnicity factor of the equation was not used because the Gubbio population is exclusively white. For the creatinine assay in the study, the MDRD equation was the best predictor of true GFR 29 and of disorders associated with low kidney function. 27 The MDRD equation has been questioned because it may underestimate the true GFR in the normal-high range 30 and in women. 27,29 To reduce these biases, main analyses were performed using a low egfr definition derived from data distribution within the study cohort, that is, using the lowest decile of the distribution analyzed separately for men and women. To avoid differences in the statistical power (ie, groups of different size), the main analyses for high UAE were conducted in a similar fashion. High UAE was defined as the highest decile of the distribution, which was analyzed separately for men and women to reduce the confounding of sex. 24,31 Three definitions were used for kidney dysfunction (categorical variable, yes or no). With the use of 1 marker, dysfunction was defined as a high UAE regardless of egfr (using UAE alone) or, alternatively, as a low egfr regardless of UAE (using egfr alone). With the use of both markers, dysfunction was defined as composite dysfunction and included high UAE without low egfr, low egfr without high UAE, or high UAE and low egfr. Other analyses focused on the thresholds suggested in clinical practice for UAE ( 20 µg/min) and egfr ( 60 ml/min/1.73 m 2 ). 1-3 CARDIOVASCULAR RISK FACTORS Hypertension was defined as a systolic pressure of 140 mm Hg or higher, a diastolic pressure of 90 mm Hg or higher, and/or reported drug treatment for hypertension. Hypercholesterolemia was defined as a serum total cholesterol level of 240 mg/dl or higher (to convert to millimoles per liter, multiply by ) and/or reported drug treatment for hypercholesterolemia. Smoking habit was self-reported information and had been validated by measurement of exhaled carbon monoxide level. 32 Diabetes mellitus was defined as a fasting serum glucose level of 126 mg/dl or higher (to convert to millimoles per liter, multiply by ) and/or reported treatment with 1 or more antidiabetic drugs or insulin. Obesity was defined as a body mass index (calculated as weight in kilograms divided by height in meters squared) of 30 or higher. Left ventricular hypertrophy was defined as high-amplitude R waves on the electrocardiogram in the absence of block patterns. PRIOR CARDIOVASCULAR DISEASE Prevalent cardiovascular disease was used as a covariate in analyses about incident events because preexisting disease predicts incident disease. 33 Prior cardiovascular disease was defined as preexisting cerebrovascular disease, ischemic heart disease, or peripheral artery disease. Cerebrovascular disease was defined as reported revascularization of a carotid artery or other cerebral arteries and/or as a reported diagnosis of ischemic or hemorrhagic stroke combined with stroke symptoms. 28 Ischemic heart disease was defined as reported revascularization of the coronary arteries and/or electrocardiographic abnormalities specific to myocardial infarction, 25,28 a criterion that aimed at reducing the misclassification of unrecognized or silent infarctions Peripheral artery disease was defined as reported revascularization of the aorta or of peripheral arteries. INCIDENT EVENTS The end point of the analyses was the incidence of events (hospitalizations and deaths) between the baseline examination and the censoring date (May 31, 2001, for living persons or the date of death for fatal events). Diagnoses from hospitalizations and mortality data (municipal registry) were systematically collected. This information was reviewed by an independent observer (A.M.) for coherence with reported data and coded according to the World Health Organization s International Classification of Diseases, Ninth Revision (ICD-9). For the definition of preexisting cardiovascular disease, an incident cardiovascular disease was defined as an event that signaled cerebrovascular disease, ischemic heart disease, or peripheral artery disease. Incident cerebrovascular disease was defined as a hospitalization with revascularization of a carotid artery or other cerebral arteries or with a diagnosis of ischemic or hemorrhagic stroke (ICD-9 codes , 436, or 433, nonfatal event) or as death due to ischemic or hemorrhagic stroke (ICD-9 codes , fatal event). Incident ischemic heart disease was defined as a hospitalization with revascularization of the coronary arteries or with a diagnosis of myocardial infarction (ICD-9 codes or 414, nonfatal event) or as death due to myocardial infarction (ICD-9 codes , fatal event). Incident peripheral artery disease was defined as a hospitalization with revascularization of the aorta or of other peripheral arteries (ICD-9 code 441, nonfatal event) or with a diagnosis of aortic aneurysm or as death due to aortic aneurysm (ICD-9 code 441, fatal event). An incident event for other diseases was defined as death (not hospitalization) for causes other than those defined as cardiovascular disease. In the case of a nonfatal event followed by a fatal event, priority was given to the nonfatal event. In the case of multiple causes of death, a hierarchical system was used giving priority to violent causes, advanced cancer, ischemic heart disease, and cerebrovascular disease, in that order. STATISTICAL ANALYSIS The main analyses were designed to compare the definitions of dysfunction based on the population-derived thresholds of kidney function (highest decile for UAE and lowest decile for egfr). Ancillary analyses focused on the data for the thresholds of kidney function suggested in clinical practice (UAE, 20 µg/min; egfr, 60 ml/min/1.73 m 2 ) and on the relation of UAE or egfr to cardiovascular events in individuals without kidney dysfunction. 618

3 160 Men Women egfr, ml/min/1.73 m UAE, µg/min Figure 1. Plot of estimated glomerular filtration rate (egfr) over urinary albumin excretion (UAE) in men and women aged 45 to 64 years. Estimated GFR and UAE were not correlated with each other (correlation coefficients, 0.035; P.15 in partial correlation analysis for men and women combined with control for sex, and in Pearson correlation analyses done separately for men and women). Statistical procedures included 2 analysis with calculation of odds ratio (OR), McNemar test, correlation analysis, proportional hazard ratio (HR) by Cox regression, and 95% confidence interval (CI). The discriminant power for incident events was assessed by receiver operating characteristic curves with calculation of the area under the curve (AUC). RESULTS Nineteen of the 1684 individuals with baseline ages of 45 to 64 years in the Gubbio population were excluded because of missing electrocardiographic data. Thus, the study cohort was composed of 1665 individuals. Descriptive statistics in the whole cohort for baseline values of cardiovascular risk factors and kidney function were previously reported with and without inclusion of diabetic individuals The mean (SD) for the interval between the baseline examination and the censoring date was 10.4 (2.2) years. The number of person-years was The number of events was 110 for cardiovascular disease and 86 for other diseases. The incidence of events was 0.64% per year for cardiovascular disease and 0.50% per year for other diseases. UAE AND egfr AS SEPARATE MARKERS OF KIDNEY DYSFUNCTION The cutoff for high UAE (highest decile) was µg/ min or higher in men and µg/min or higher in women. The cutoff for low egfr (lowest decile) was less than ml/min/1.73 m 2 in men and less than ml/min/1.73 m 2 in women. With the use of a single marker (high UAE alone or low egfr alone, alternatively), 1498 individuals (90.0%) were defined as having no dysfunction and 167 individuals (10.0%) as having dysfunction (74 men and 93 women). The number of individuals with dysfunction was identical using UAE or egfr, as expected according to the decile-based definition. With the use of both markers (composite dysfunction), only 1354 individuals (81.3%) were defined as having no dysfunction and 311 (18.7%) as having dysfunction (1.86 times higher than the number using a single marker, P.001). These changes in the number of individuals with or without dysfunction reflected the weak association between high UAE and low egfr (P=.12) that clustered in different subgroups as shown by the following cross-tabulation: 1354 individuals without high UAE and without low egfr; 144 individuals with high UAE and without low egfr (isolated high UAE); 144 individuals with low egfr and without high UAE (isolated low egfr); and 23 individuals with high UAE and low egfr. Thus, when we used high UAE alone, 144 individuals were defined as having no dysfunction despite having a low egfr. When we used low egfr alone, 144 individuals were defined as having no dysfunction despite having a high UAE. The markers UAE and egfr were also not associated with each other in analyses using clinical thresholds of kidney function (association between a UAE of 20 µg/ min and an egfr of 60 ml/min/1.73 m 2, n=77 and n=177, respectively [P=.94]) and in analyses across the whole range of UAE and egfr values (Figure 1). 619

4 Table 1. Indexes of Kidney Function and Other Variables or Prevalence by Presence and Type of Baseline Kidney Dysfunction in Individuals Aged 45 to 64 Years Variable No Kidney Dysfunction (n=1354) Isolated High UAE b (n=144) Composite Kidney Dysfunction a High UAE and Low egfr (n=23) Isolated Low egfr c (n=144) UAE, mean (SD), µg/min 7.8 (4.4) 50.5 (179.2) (210.4) 7.7 (4.6) Serum creatinine level, mean (SD), mg/dl 0.93 (0.14) 0.93 (0.15) 1.26 (0.13) 1.21 (0.13) egfr, mean (SD), ml/min/1.73 m (12.7) 77.7 (14.5) 57.2 (5.6) 56.0 (4.5) Women, % Age, mean (SD), y 54.5 (5.6) 55.5 (5.1) 57.7 (5.0) 56.9 (5.5) Prevalent cardiovascular risk factors Systolic pressure, mean (SD), mm Hg (17.0) (21.6) (17.5) (17.9) Diastolic pressure, mean (SD), mm Hg 77.7 (9.3) 85.5 (11.0) 84.4 (6.7) 78.8 (8.8) Antihypertensive drug use, % Hypertension, % Serum total cholesterol level, mean (SD), mg/dl (37.6) (43.0) (32.7) (37.0) Serum HDL cholesterol level, mean (SD), mg/dl 50.7 (12.8) 50.0 (13.1) 51.1 (15.1) 48.1 (11.1) Hypercholesterolemia, % Current smokers, % Serum glucose level, mean (SD), mg/dl 94.3 (20.2) 99.1 (27.9) 96.9 (20.0) 92.1 (14.4) Diabetes mellitus, % Left ventricular hypertrophy, % BMI, mean (SD) 27.8 (4.2) 30.1 (4.6) 31.2 (5.7) 28.0 (4.2) Obesity, % Prior cardiovascular disease, % Cerebrovascular disease Ischemic heart disease Peripheral artery disease Any of the above Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); egfr, estimated glomerular filtration rate; HDL, high-density lipoprotein; UAE, urinary albumin excretion. SI conversion factors: To convert total and HDL cholesterol to millimoles per liter, multiply by ; creatinine to micromoles per liter, multiply by 88.4; and glucose to millimoles per liter, multiply by a Indicates with high UAE (highest sex-specific decile) or with low egfr (lowest sex-specific decile). b Indicates with high UAE and without low egfr. c Indicates with low egfr and without high UAE. KIDNEY DYSFUNCTION AND BASELINE CORRELATES Table 1 shows the baseline values of kidney function and other variables in individuals without dysfunction and in individuals with dysfunction according to the type of dysfunction (isolated high UAE, high UAE and low egfr, or isolated low egfr). Cardiovascular risk factors were more prevalent in individuals with dysfunction than in individuals without dysfunction. The difference was significant for hypertension, hypercholesterolemia, and obesity in individuals with isolated high UAE (OR, 2.6 [P.001]); for hypertension, hypercholesterolemia, obesity, and left ventricular hypertrophy in individuals with high UAE and low egfr (OR, 3.0 [P.01]); and only for hypertension in individuals with isolated low egfr (OR, 1.46 [P=.04]). Prior cardiovascular disease was more prevalent in all subgroups with dysfunction than in individuals without dysfunction (OR, 2.2 [P.04]). Prior cardiovascular disease was more prevalent in individuals with high UAE and low egfr than in individuals with isolated high UAE and isolated low egfr combined (OR, 3.58 [P=.03]). KIDNEY DYSFUNCTION AND INCIDENT EVENTS The incidence of events was higher in individuals with high UAE than in individuals without high UAE for cardiovascular disease (12.0% vs 6.0%; OR, 2.13 [P=.003]) but not for other diseases (7.2% vs 4.9%; OR, 1.49 [P=.21]). The HR for cardiovascular events in individuals with high UAE was 2.15 (95% CI, ) and did not change when we excluded the 9 individuals with macroalbuminuria (UAE, 200 µg/min) (HR, 2.14; 95% CI, ). Results were similar using the clinical threshold for UAE (UAE, 20 µg/min vs 20 µg/min) (HR, 2.81; 95% CI, ). The incidence of events in individuals with low egfr was higher than in individuals without low egfr for cardiovascular disease (12.0% vs 6.0%; OR, 2.13 [P=.003]) but not for other diseases (4.8% vs 5.2%; OR, 0.92 [P=.82]). The HR for cardiovascular events in individuals with low egfr was 2.14 (95% CI, ). Results were similar using the clinical threshold for egfr ( 60 vs 60 ml/ min/1.73 m 2 ) (HR, 1.64; 95% CI, ). The incidence of cardiovascular events by the presence and type of kidney dysfunction is shown as a per- 620

5 Table 2. Incidence of Cardiovascular Disease and Other Disease Events by Presence and Type of Baseline Kidney Dysfunction in Individuals Aged 45 to 64 Years Cardiovascular and Other Disease Events, % of Patients No Kidney Dysfunction Isolated High UAE b Composite Kidney Dysfunction a High UAE and Low egfr Isolated Low egfr c Cerebrovascular disease Ischemic heart disease Peripheral artery disease Any of the above Nonfatal Fatal Other diseases Event-Free Survival No kidney dysfunction Isolated low egfr Isolated high UAE High UAE and low egfr Time, y Abbreviations: egfr, estimated glomerular filtration rate; UAE, urinary albumin excretion. a Indicates with high UAE (highest sex-specific decile) or with low egfr (lowest sex-specific decile). b Indicates with high UAE and without low egfr. c Indicates with low egfr and without high UAE. centage rate in Table 2 and as a Kaplan-Meier plot in Figure 2. Compared with individuals without dysfunction, the HR for a cardiovascular event was 1.85 in individuals with isolated high UAE (95% CI, ), 1.84 in individuals with isolated low egfr (95% CI, ), and 5.93 in individuals with high UAE and low egfr (95% CI, ). The elevated HR in individuals with high UAE and low egfr suggested an interaction between high UAE and low egfr. The interaction was significant because the HR for cardiovascular events was higher in individuals with high UAE and low egfr than individuals with isolated high UAE and isolated low egfr combined (HR, 3.19; 95% CI, ). When kidney dysfunction was defined using both markers (composite dysfunction), the HR for cardiovascular events was 2.09 compared with no kidney dysfunction (95% CI, ). Findings were similar when this HR was calculated separately for men and women (2.22 and 2.10, respectively), for nonfatal and fatal events (1.89 and 3.97, respectively), and for ischemic heart disease and other cardiovascular disease (2.10 and 1.84, respectively). MULTIVARIATE ANALYSES Table 3 shows the HR for cardiovascular events associated with kidney dysfunction and other variables in multivariate Cox models. Analyses were limited to the kidney dysfunction defined using both markers (composite dysfunction) compared with no kidney dysfunction because definitions using 1 marker misclassified individuals with isolated low egfr (definition by high UAE alone) or with isolated high UAE (definition by low egfr alone). The following 3 models were analyzed for investigation about different presentations of incident cardiovascular disease: model 1 for first events (nonfatal and fatal events in individuals without prior cardiovascular disease); model 2 for first or recurrent events (nonfatal and Figure 2. Kaplan-Meier plot of incident cardiovascular events in individuals aged 45 to 64 years. No kidney dysfunction (n=1354 without high urinary albumin excretion [UAE] and without low estimated glomerular filtration rate [egfr]) compared with kidney dysfunction divided subjects into the following 3 subgroups: isolated high UAE (n=144 with high UAE and without low egfr), isolated low egfr (n=144 with low egfr and without high UAE), and high UAE and low egfr (n=23). High UAE was defined as a UAE in the highest sex-specific decile, and low egfr was defined as an egfr in the lowest sex-specific decile. fatal events in the whole cohort including individuals with prior cardiovascular disease); and model 3 for fatal events (fatal events only in the entire cohort). The HR of kidney dysfunction was significant in all models. Three similar additional models were analyzed using categorical variables as follows: obesity replacing body mass index, hypertension replacing systolic pressure and antihypertensive treatment, and hypercholesterolemia replacing serum total cholesterol level. The HR of composite dysfunction was elevated in these models (HRs, 1.41, 1.45, and 2.49, respectively [P.05]). For the additional categorical variables, HR was never significant for obesity (P.5), significant for hypercholesterolemia in models on nonfatal and fatal events in the entire cohort (HRs, 1.55 and 1.58, respectively [P.05]), and significant for hypertension in all models (HRs, 1.80, 1.92, and 1.98, respectively [P.05]). The area under the receiver operating characteristic curve of composite dysfunction was (P=.02), a value that ranked between the AUCs of hypertension, smoking, and hypercholesterolemia (0.601, 0.572, and 0.570, respectively [P.01]) and the AUCs of prior cardiovascular disease, left ventricular hypertrophy, diabetes mellitus, and obesity (0.541, 0.534, 0.524, and 0.517, respectively [P.15]). The AUC of composite dysfunction was higher for fatal events than for nonfatal events (0.639 [P=.054] and [P=.07], respectively). RELATION OF UAE AND egfr TO EVENTS IN INDIVIDUALS WITHOUT KIDNEY DYSFUNCTION In analyses limited to individuals without high UAE ( µg/min in men and µg/min in women), the incidence of cardiovascular events did not differ among UAE tertiles (6.2%, 7.5%, and 6.1% [P=.35]). The relation between UAE and events was not signifi- 621

6 Table 3. Hazard Ratios for Incident Cardiovascular Disease of Kidney Dysfunction Defined by 2 Markers (Composite Dysfunction a ) and Other Variables in Multivariate Cox Models for Individuals Aged 45 to 64 Years Incident Cardiovascular Disease b Variable All (Nonfatal and Fatal) All (Nonfatal and Fatal) Fatal Only No. of individuals 1611 c 1665 d 1665 d No. of events Composite kidney dysfunction, a (yes vs no) 1.47 ( ) e 1.50 ( ) e 3.03 ( ) f Sex (men vs women) 4.23 ( ) g 3.88 ( ) g 8.69 ( ) g Age, y (55-64 vs y) 1.27 h 1.32 h 1.47 h Systolic pressure 1 SD (18 mm Hg) 1.25 ( ) e 1.12 h 1.24 ( ) i Antihypertensive drug treatment (yes vs no) 1.91 ( ) f 2.21 ( ) g 1.60 h Serum total cholesterol 1 SD (40 mg/dl) 1.17 h 1.21 ( ) e 1.19 h Serum HDL cholesterol 1 SD (13 mg/dl) 0.85 h 0.90 h 1.01 h Smoking (yes vs no) 1.63 ( ) e 1.66 ( ) f 2.40 ( ) e Diabetes (yes vs no) 1.03 h 1.27 h 2.49 ( ) Left ventricular hypertrophy (yes vs no) 2.24 ( ) e 2.48 ( ) f 1.41 h Prior cardiovascular disease (yes vs no) Not included in the model 2.59 ( ) f 4.81 ( ) g BMI 1 SD (4.3) 1.13 h 1.11 h 1.44 ( ) e Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); HDL, high-density lipoprotein. SI conversion factor: To convert total and HDL cholesterol to millimoles per liter, multiply by a With high urinary albumin excretion (highest sex-specific decile) or with low estimated glomerular filtration rate (lowest sex-specific decile). b Unless otherwise indicated, data are expressed as hazard ratio (95% confidence interval). c Indicates without prior cardiovascular disease. d Indicates whole cohort. e P.05. f P.01. g P.001. h P.10; therefore, no 95% confidence interval is given. i P.10 and P.05. cant in any analysis limited to these individuals, even when using UAE as a continuous variable (data not shown). In analyses limited to individuals without low egfr ( ml/min/1.73 m 2 in men and ml/min/ 1.73 m 2 in women), the incidence of cardiovascular events did not differ among egfr tertiles (8.2%, 6.3%, and 6.3% [P=.13]). The relation between egfr and events was not significant in any analysis limited to these individuals, even when using egfr as a continuous variable (data not shown). COMMENT This population-based study reports several new observations in support of the idea that the measurement of 2 markers of kidney function UAE and egfr provides additional and independent information for assessing cardiovascular risk. First, the 2 markers were not associated with each other as proved by analyses using the highest UAE decile and the lowest egfr decile, by analyses using clinical definitions of altered UAE and egfr, and by analyses on the entire range of UAE and egfr values. The lack of the association between these 2 markers implied that high UAE and low egfr tended to mark separate groups in the population and that the number of individuals defined as having kidney dysfunction was higher when using both markers than when using one. Second, high UAE and low egfr were associated with high cardiovascular risk independently of each other, as proved by data for the subgroups with isolated high UAE or isolated low egfr. The association with cardiovascular disease was of similar strength for high UAE and low egfr, significant longitudinally (as well as crosssectionally), and independent of the few individuals carrying both markers of kidney dysfunction (high UAE and low egfr). Third, for prediction of cardiovascular disease, the definition of dysfunction based on both markers had a discriminant power similar to that of traditional factors. In addition, the study provides further information on the independence of the association between kidney dysfunction and cardiovascular disease showing that, when defined by both markers, the association of dysfunction with cardiovascular disease is statistically independent of several other factors. Caution should be used in extrapolating these observations to other populations given that the study involved only middleaged white subjects with a low prevalence of diabetes mellitus. The present results agree with reports of a relation between microalbuminuria and incident cardiovascular disease, 7-9 confirming that the relation exists also with nonfatal events. 9 For low egfr and incident cardiovascular disease, the results support the large number of studies reporting an independent relation. 10,12,15-21 The sample size and the number of events were the major limitations of this study. These limitations affected the power of the study but were unlikely to cause a substantial bias because the results for traditional predictors of cardiovascular risk were in agreement with expectations for middle-aged persons. For UAE, the absolute urinary excretion was preferred to the ratio of urinary albumin to creatinine levels to avoid the misclassifica- 622

7 tion of individuals with a high ratio secondary to low muscular mass. 26 For egfr, the method used in the study was the best predictor of true GFR in clinical settings 29 and of disorders associated with low kidney function in the population. 27 The use of cutoffs derived from the sexspecific distribution of kidney function in the population was designed to achieve groups of similar size and to reduce the bias secondary to laboratory-specific factors 37 or to the effects of sex on UAE 24,31 and egfr. 27,38 These results have practical implications on the usefulness of the assessment of kidney function in the estimation of cardiovascular risk. The findings appear meaningful from a clinical viewpoint because the excess of cardiovascular disease associated with kidney dysfunction was of a magnitude similar to that associated with traditional factors. Analyses of the mechanisms linking kidney dysfunction to cardiovascular disease were beyond the aims of this study. High UAE is considered a sign of endothelial damage secondary to uncontrolled cardiovascular risk factors. 1-3 For egfr, several factors could represent a link between a low GFR and increased cardiovascular risk (eg, activation of the renin-angiotensin system, anemia, and hyperhomocysteinemia). 1-3 The data support the view that high UAE and low egfr are separate entities in relation to cardiovascular risk because the 2 markers clustered in different groups and predicted cardiovascular disease independently of each other. The interaction between high UAE and low egfr in the prediction of cardiovascular risk suggests some interdependence between the underlying mechanisms, although the small number of individuals with high UAE and low egfr suggests that further investigation in larger samples is needed. Altogether these results agree with the concept that kidney dysfunction may be regarded as a quantifiable index of cardiovascular risk. The lack of a continuous relation across the whole range of UAE and egfr supports the view that the relation is nonlinear and significant only beyond a given threshold. 39 CONCLUSIONS This study shows that high UAE and low egfr do not run together in the population. The use of only 1 of these 2 markers underscores the potential to misclassify patients as having no kidney dysfunction, resulting in less intensive management of their disease. Also, the association of kidney dysfunction with cardiovascular disease is highlighted because high UAE and low egfr mark different groups of persons with high cardiovascular risk. Further studies are needed to explore the factors responsible for the different expression of kidney dysfunction and the possible countermeasures. Accepted for Publication: October 15, Correspondence: Massimo Cirillo, MD, Nefrologia (Ed 17) Policlinico, via Sergio Pansini 5, Naples, Italy (massimo.cirillo@unina2.it). Author Contributions: Study concept and design: Cirillo, Laurenzi, Mancini, and Zanchetti. Acquisition of data: Cirillo, Lanti, Laurenzi, and De Santo. Analysis and interpretation of data: Cirillo, Menotti, and De Santo. Drafting of the manuscript: Cirillo and Laurenzi. Critical revision of the manuscript for important intellectual content: Cirillo, Lanti, Menotti, Mancini, Zanchetti, and De Santo. Statistical analysis: Cirillo, Lanti, and Menotti. Obtained funding: Laurenzi. Administrative, technical, and material support: Laurenzi. Study supervision: Mancini, Zanchetti, and De Santo. Financial Disclosure: None reported. Funding/Support: This study was supported by Merck Sharp & Dohme Italy for study design, implementation, and data collection. Additional Contributions: The Gubbio Study was made possible thanks to the people and the local authorities of Gubbio in collaboration with Merck Sharp & Dohme Italy; Center for Preventive Medicine, Gubbio; Gubbio Hospital; Federico II University; University of Milan; Northwestern University of Chicago, Illinois; Istituto Superiore di Sanità, Rome, Italy; and Second University of Naples. REFERENCES 1. Sarnak MJ, Levey AS, Schoolwerth AC, et al; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108(17): Levey AS, Coresh J, Balk E, et al; National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification [published correction appears in Ann Intern Med. 2003;139(7):605]. Ann Intern Med. 2003;139(2): European Society of Hypertension European Society of Cardiology Guidelines Committee European Society of Hypertension European Society of Cardiology guidelines for the management of arterial hypertension [published corrections appear in J Hypertens. 2003;21(11): and J Hypertens. 2004;22(2):435]. J Hypertens. 2003;21(6): Culleton BF, Larson MG, Parfrey PS, Kannel WB, Levy D. Proteinuria as a risk factor for cardiovascular disease and mortality in older people: a prospective study. Am J Med. 2000;109(1): Madison JR, Spies C, Schatz IJ, et al. Proteinuria and risk for stroke and coronary heart disease during 27 years of follow-up: the Honolulu Heart Program. Arch Intern Med. 2006;166(8): Halbesma N, Kuiken DS, Brantsma AH, et al. Microalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening. J Am Soc Nephrol. 2006;17(9): Hillege HL, Fidler V, Diercks GFH, et al; Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106(14): Yuyun MF, Khaw K-T, Luben R, et al. A prospective study of microalbuminuria and incident coronary heart disease and its prognostic significance in a British population. Am J Epidemiol. 2004;159(3): Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355(25): Wannamethee SG, Shaper AG, Perry IJ. Serum creatinine concentration and risk of cardiovascular disease: a possible marker for increased risk of stroke. Stroke. 1997;28(3): Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 1999;56(6): Henry RM, Kostense PJ, Bos G, et al. Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn Study. Kidney Int. 2002;62(4): Garg AX, Clark WF, Haynes RB, House AA. Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney Int. 2002; 61(4): Jurkovitz CT, Abramson JL, Vaccarino V, Weintraub WS, McClellan WM. Asso- 623

8 ciation of high serum creatinine and anemia increases the risk of coronary events: results from the Prospective Community-Based Atherosclerosis Risk in Communities (ARIC) Study. J Am Soc Nephrol. 2003;14(11): Fried LF, Shlipak MG, Crump C, et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol. 2003; 41(8): Abramson JL, Jurkovitz CT, Vaccarino V, Weintraub W, McClellan W. Chronic kidney disease, anemia, and incident stroke in a middle-aged, communitybased population: the ARIC Study. Kidney Int. 2003;64(2): Manjunath G, Tighiouart H, Coresh J, et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int. 2003;63(3): Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351(13): Shlipak MG, Fried LF, Cushman M, et al. Cardiovascular mortality risk in chronic kidney disease. JAMA. 2005;293(14): Meisinger C, Döring A, Löwel H; KORA Study Group. Chronic kidney disease and risk of incident myocardial infarction and all-cause and cardiovascular disease mortality in middle-aged men and women from the general population. Eur Heart J. 2006;27(10): Weiner DE, Tabatabai S, Tighiouart H, et al. Cardiovascular outcomes and allcause mortality: exploring the interaction between CKD and cardiovascular disease. Am J Kidney Dis. 2006;48(3): Laurenzi M, Cirillo M, Angeletti M, et al. Gubbio Population Study: baseline findings. Nutr Metab Cardiovasc Dis. 1991;1(4)(suppl):S1-S Laurenzi M, Cirillo M, Panarelli W, et al. Baseline sodium-lithium countertransport and 6-year incidence of hypertension: the Gubbio Population Study. Circulation. 1997;95(3): Cirillo M, Senigalliesi L, Laurenzi M, et al. Microalbuminuria in non-diabetic adults: relation of blood pressure, body mass, plasma cholesterol, and smoking: the Gubbio Population Study. Arch Intern Med. 1998;158(17): Cirillo M, Laurenzi M, Panarelli P, Mancini M, Zanchetti A, De Santo NG. Relation of urinary albumin excretion to coronary heart disease and low renal function: role of blood pressure. Kidney Int. 2004;65(6): Cirillo M, Laurenzi M, Mancini M, Zanchetti A, De Santo NG. Low muscular mass and overestimation of microalbuminuria by urinary albumin/creatinine ratio. Hypertension. 2006;47(1): Cirillo M, Laurenzi M, Mancini M, Zanchetti A, De Santo NG. Low glomerular filtration in the population: prevalence, associated disorders, and awareness. Kidney Int. 2006;70(4): Rose GA, Blackburn H, Gillman RF, Prineas RJ. Cardiovascular Survey Methods. Geneva, Switzerland: World Health Organization; Cirillo M, Anastasio P, Santo NG. Relationship of gender, age, and body mass index to error in predicted kidney function. Nephrol Dial Transplant. 2005;20 (9): Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med. 2004;141(12): Mattix HJ, Hsu CY, Shaykevich S, Curhan G. Use of the albumin/creatinine ratio to detect microalbuminuria: implications of sex and race. J Am Soc Nephrol. 2002; 13(4): Cirillo M, Laurenzi M, Trevisan M, Stamler J. Hematocrit, blood pressure, and hypertension: the Gubbio Population Study. Hypertension. 1992;20(3): Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile: a statement for health professionals. Circulation. 1991;83(1): Sheifer SE, Manolio TA, Gersh BJ. Unrecognized myocardial infarction. Ann Intern Med. 2001;135(9): Boland LL, Folsom AR, Sorlie PD, et al. Occurrence of unrecognized myocardial infarction in subjects aged 45 to 65 years (the ARIC study). Am J Cardiol. 2002; 90(9): Cohn PF, Fox KM, Daly C. Silent myocardial ischemia. Circulation. 2003;108(10): Coresh J, Astor BC, McQuillan G, et al. Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis. 2002;39(5): Froissart M, Rossert J, Jacquot C, Paillard M, Houillier P. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol. 2005;16(3): Hostetter TH. Chronic kidney disease predicts cardiovascular disease. N Engl J Med. 2004;351(13):

Astatement of the American Heart Association and guidelines

Astatement of the American Heart Association and guidelines Low Muscular Mass and Overestimation of Microalbuminuria by Urinary Albumin/Creatinine Ratio Massimo Cirillo, Martino Laurenzi, Mario Mancini, Alberto Zanchetti, Natale G. De Santo Abstract Microalbuminuria

More information

Massimo Cirillo, Cinzia Lombardi, Giancarlo Bilancio, Daniela Chiricone, Davide Stellato, and Natale G. De Santo

Massimo Cirillo, Cinzia Lombardi, Giancarlo Bilancio, Daniela Chiricone, Davide Stellato, and Natale G. De Santo Urinary Albumin and Cardiovascular Profile in the Middle-Aged Population Massimo Cirillo, Cinzia Lombardi, Giancarlo Bilancio, Daniela Chiricone, Davide Stellato, and Natale G. De Santo The moderate increase

More information

Chronic kidney disease (CKD) has received

Chronic kidney disease (CKD) has received Participant Follow-up in the Kidney Early Evaluation Program (KEEP) After Initial Detection Allan J. Collins, MD, FACP, 1,2 Suying Li, PhD, 1 Shu-Cheng Chen, MS, 1 and Joseph A. Vassalotti, MD 3,4 Background:

More information

YOUNG ADULT MEN AND MIDDLEaged

YOUNG ADULT MEN AND MIDDLEaged BRIEF REPORT Favorable Cardiovascular Profile in Young Women and Long-term of Cardiovascular and All-Cause Mortality Martha L. Daviglus, MD, PhD Jeremiah Stamler, MD Amber Pirzada, MD Lijing L. Yan, PhD,

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines

More information

THE PROGNOSIS OF PATIENTS WITH CHRONIC KIDNEY DISEASE AND DIABETES MELLITUS

THE PROGNOSIS OF PATIENTS WITH CHRONIC KIDNEY DISEASE AND DIABETES MELLITUS 214 ILEX PUBLISHING HOUSE, Bucharest, Roumania http://www.jrdiabet.ro Rom J Diabetes Nutr Metab Dis. 21(3):23-212 doi: 1.2478/rjdnmd-214-25 THE PROGNOSIS OF PATIENTS WITH CHRONIC KIDNEY DISEASE AND DIABETES

More information

Cardiovascular and renal outcome in subjects with K/DOQI stage 1 3 chronic kidney disease: the importance of urinary albumin excretion

Cardiovascular and renal outcome in subjects with K/DOQI stage 1 3 chronic kidney disease: the importance of urinary albumin excretion Nephrol Dial Transplant (2008) 23: 3851 3858 doi: 10.1093/ndt/gfn356 Advance Access publication 18 July 2008 Original Article Cardiovascular and renal outcome in subjects with K/DOQI stage 1 3 chronic

More information

CHRONIC KIDNEY DISEASE (CKD) is a

CHRONIC KIDNEY DISEASE (CKD) is a Cardiovascular Outcomes and All-Cause Mortality: Exploring the Interaction Between CKD and Cardiovascular Disease Daniel E. Weiner, MD, MS, Sayed Tabatabai, MD, Hocine Tighiouart, MS, Essam Elsayed, MD,

More information

A: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups

A: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were

More information

1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria

1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria 1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage

More information

CVD risk assessment using risk scores in primary and secondary prevention

CVD risk assessment using risk scores in primary and secondary prevention CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and

More information

egfr > 50 (n = 13,916)

egfr > 50 (n = 13,916) Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according

More information

Cardiovascular Risk Among Adults With Chronic Kidney Disease, With or Without Prior Myocardial Infarction

Cardiovascular Risk Among Adults With Chronic Kidney Disease, With or Without Prior Myocardial Infarction Journal of the American College of Cardiology Vol. 48, No. 6, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.05.047

More information

ORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults

ORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults ORIGINAL INVESTIGATION C-Reactive Protein Concentration and Incident Hypertension in Young Adults The CARDIA Study Susan G. Lakoski, MD, MS; David M. Herrington, MD, MHS; David M. Siscovick, MD, MPH; Stephen

More information

GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS

GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental

More information

Long-term outcomes in nondiabetic chronic kidney disease

Long-term outcomes in nondiabetic chronic kidney disease original article http://www.kidney-international.org & 28 International Society of Nephrology Long-term outcomes in nondiabetic chronic kidney disease V Menon 1, X Wang 2, MJ Sarnak 1, LH Hunsicker 3,

More information

The CARI Guidelines Caring for Australians with Renal Impairment. 5. Classification of chronic kidney disease based on evaluation of kidney function

The CARI Guidelines Caring for Australians with Renal Impairment. 5. Classification of chronic kidney disease based on evaluation of kidney function 5. Classification of chronic kidney disease based on evaluation of kidney function Date written: April 2005 Final submission: May 2005 GUIDELINES No recommendations possible based on Level I or II evidence

More information

AGING KIDNEY IN HIV DISEASE

AGING KIDNEY IN HIV DISEASE AGING KIDNEY IN HIV DISEASE Michael G. Shlipak, MD, MPH Professor of Medicine, Epidemiology and Biostatistics, UCSF Chief, General Internal Medicine, San Francisco VA Medical Center Kidney, Aging and HIV

More information

Chronic Kidney Disease is Associated with Cognitive Decline: the Northern Manhattan Study (NOMAS) Seattle VA Chief of Medicine Rounds June 9, 2009

Chronic Kidney Disease is Associated with Cognitive Decline: the Northern Manhattan Study (NOMAS) Seattle VA Chief of Medicine Rounds June 9, 2009 Chronic Kidney Disease is Associated with Cognitive Decline: the Northern Manhattan Study (NOMAS) Seattle VA Chief of Medicine Rounds June 9, 2009 Minesh Khatri Internal Medicine R2 Background Patients

More information

The relation between estimated glomerular filtration rate and proteinuria in Okayama Prefecture, Japan

The relation between estimated glomerular filtration rate and proteinuria in Okayama Prefecture, Japan Environ Health Prev Med (2011) 16:191 195 DOI 10.1007/s12199-010-0183-9 SHORT COMMUNICATION The relation between estimated glomerular filtration rate and proteinuria in Okayama Prefecture, Japan Nobuyuki

More information

ORIGINAL INVESTIGATION. Cross-Classification of Microalbuminuria and Reduced Glomerular Filtration Rate

ORIGINAL INVESTIGATION. Cross-Classification of Microalbuminuria and Reduced Glomerular Filtration Rate ORIGINAL INVESTIGATION Cross-Classification of Microalbuminuria and Glomerular Filtration Rate Associations Between Cardiovascular Disease Risk Factors and Clinical Outcomes Meredith C. Foster, BA; Shih-Jen

More information

Cardiovascular disease (CVD) is the leading cause of morbidity

Cardiovascular disease (CVD) is the leading cause of morbidity Effects of Anemia and Left Ventricular Hypertrophy on Cardiovascular Disease in Patients with Chronic Kidney Disease Daniel E. Weiner,* Hocine Tighiouart, Panagiotis T. Vlagopoulos,* John L. Griffith,

More information

The incidence and prevalence of hypertension

The incidence and prevalence of hypertension Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004 Madhav V. Rao, MD, 1 Yang Qiu, MS, 2 Changchun Wang, MS, 2 and George

More information

Central pressures and prediction of cardiovascular events in erectile dysfunction patients

Central pressures and prediction of cardiovascular events in erectile dysfunction patients Central pressures and prediction of cardiovascular events in erectile dysfunction patients N. Ioakeimidis, K. Rokkas, A. Angelis, Z. Kratiras, M. Abdelrasoul, C. Georgakopoulos, D. Terentes-Printzios,

More information

Chapter 1: CKD in the General Population

Chapter 1: CKD in the General Population Chapter 1: CKD in the General Population Overall prevalence of CKD (Stages 1-5) in the U.S. adult general population was 14.8% in 2011-2014. CKD Stage 3 is the most prevalent (NHANES: Figure 1.2 and Table

More information

( 1) Framingham Heart

( 1) Framingham Heart ( 1) ( 1) Framingham Heart Study [1] 1. (Am J Kidney Dis. 45: 223-232, 2005) 96 19 1 17 Framingham Heart Study ( 1) American Heart Association (1) (2) (3) (4) [2] (GFR) [3] ARIC [4] Cardiovascular Health

More information

Predicting and changing the future for people with CKD

Predicting and changing the future for people with CKD Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University

More information

Predicting cardiovascular risk in the elderly in different European countries

Predicting cardiovascular risk in the elderly in different European countries European Heart Journal (2002) 23, 294 300 doi:10.1053/euhj.2001.2898, available online at http://www.idealibrary.com on Predicting cardiovascular risk in the elderly in different European countries S.

More information

Is the new Mayo Clinic Quadratic (MCQ) equation useful for the estimation of glomerular filtration rate in type 2 diabetic patients?

Is the new Mayo Clinic Quadratic (MCQ) equation useful for the estimation of glomerular filtration rate in type 2 diabetic patients? Diabetes Care Publish Ahead of Print, published online October 3, 2008 The MCQ equation in DM2 patients Is the new Mayo Clinic Quadratic (MCQ) equation useful for the estimation of glomerular filtration

More information

Chronic Kidney Disease Increases Cardiovascular Mortality in 80-Year-Old Subjects in Japan

Chronic Kidney Disease Increases Cardiovascular Mortality in 80-Year-Old Subjects in Japan 2053 Original Article Hypertens Res Vol.31 (2008) No.11 p.2053-2058 Chronic Kidney Disease Increases Cardiovascular Mortality in 80-Year-Old Subjects in Japan Shuntaro KAGIYAMA 1),2), Kiyoshi MATSUMURA

More information

Figure 1 LVH: Allowed Cost by Claim Volume (Data generated from a Populytics analysis).

Figure 1 LVH: Allowed Cost by Claim Volume (Data generated from a Populytics analysis). Chronic Kidney Disease (CKD): The New Silent Killer Nelson Kopyt D.O. Chief of Nephrology, LVH Valley Kidney Specialists For the past several decades, the health care needs of Americans have shifted from

More information

S150 KEEP Analytical Methods. American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153

S150 KEEP Analytical Methods. American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153 S150 KEEP 2009 Analytical Methods American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153 S151 The Kidney Early Evaluation program (KEEP) is a free, communitybased health screening

More information

E.Ritz Heidelberg (Germany)

E.Ritz Heidelberg (Germany) Predictive capacity of renal function in cardiovascular disease E.Ritz Heidelberg (Germany) If a cure is not achieved, the kidneys will pass on the disease to the heart Huang Ti Nei Ching Su Wen The Yellow

More information

Analytical Methods: the Kidney Early Evaluation Program (KEEP) The Kidney Early Evaluation program (KEEP) is a free, community based health

Analytical Methods: the Kidney Early Evaluation Program (KEEP) The Kidney Early Evaluation program (KEEP) is a free, community based health Analytical Methods: the Kidney Early Evaluation Program (KEEP) 2000 2006 Database Design and Study Participants The Kidney Early Evaluation program (KEEP) is a free, community based health screening program

More information

Glomerular Filtration Rate, Albuminuria, and Risk of Cardiovascular and All-Cause Mortality in the US Population

Glomerular Filtration Rate, Albuminuria, and Risk of Cardiovascular and All-Cause Mortality in the US Population American Journal of Epidemiology ª The Author 2008. Published by the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org.

More information

Chronic kidney disease (CKD) reportedly affects

Chronic kidney disease (CKD) reportedly affects AJH 2006; 19:608 614 Kidney A Comparison of Serum Creatinine Based Methods for Identifying Chronic Kidney Disease in Hypertensive Individuals and Their Siblings Andrew D. Rule, Steven J. Jacobsen, Gary

More information

Objectives. Pre-dialysis CKD: The Problem. Pre-dialysis CKD: The Problem. Objectives

Objectives. Pre-dialysis CKD: The Problem. Pre-dialysis CKD: The Problem. Objectives The Role of the Primary Physician and the Nephrologist in the Management of Chronic Kidney Disease () By Brian Young, M.D. Assistant Clinical Professor of Medicine David Geffen School of Medicine at UCLA

More information

The CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors

The CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker

More information

USRDS UNITED STATES RENAL DATA SYSTEM

USRDS UNITED STATES RENAL DATA SYSTEM USRDS UNITED STATES RENAL DATA SYSTEM Chapter 2: Identification and Care of Patients With CKD Over half of patients from the Medicare 5 percent sample have either a diagnosis of chronic kidney disease

More information

Microalbuminuria As Predictor Of Severity Of Coronary Artery Disease In Non-Diabetic Patients:

Microalbuminuria As Predictor Of Severity Of Coronary Artery Disease In Non-Diabetic Patients: ISPUB.COM The Internet Journal of Cardiology Volume 9 Number 1 Microalbuminuria As Predictor Of Severity Of Coronary Artery Disease In Non-Diabetic Patients: F Aziz, S Penupolu, S Doddi, A Alok, S Pervaiz,

More information

Lucia Cea Soriano 1, Saga Johansson 2, Bergur Stefansson 2 and Luis A García Rodríguez 1*

Lucia Cea Soriano 1, Saga Johansson 2, Bergur Stefansson 2 and Luis A García Rodríguez 1* Cea Soriano et al. Cardiovascular Diabetology (2015) 14:38 DOI 10.1186/s12933-015-0204-5 CARDIO VASCULAR DIABETOLOGY ORIGINAL INVESTIGATION Open Access Cardiovascular events and all-cause mortality in

More information

Classification of CKD by Diagnosis

Classification of CKD by Diagnosis Classification of CKD by Diagnosis Diabetic Kidney Disease Glomerular diseases (autoimmune diseases, systemic infections, drugs, neoplasia) Vascular diseases (renal artery disease, hypertension, microangiopathy)

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Afkarian M, Zelnick L, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA. doi:10.1001/jama.2016.10924 emethods efigure

More information

ARIC Manuscript Proposal # PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority:

ARIC Manuscript Proposal # PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority: ARIC Manuscript Proposal # 1475 PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority: 1.a. Full Title: Hypertension, left ventricular hypertrophy, and risk of incident hospitalized

More information

CARDIOVASCULAR RISK ASSESSMENT ADDITION OF CHRONIC KIDNEY DISEASE AND RACE TO THE FRAMINGHAM EQUATION PAUL E. DRAWZ, MD, MHS

CARDIOVASCULAR RISK ASSESSMENT ADDITION OF CHRONIC KIDNEY DISEASE AND RACE TO THE FRAMINGHAM EQUATION PAUL E. DRAWZ, MD, MHS CARDIOVASCULAR RISK ASSESSMENT ADDITION OF CHRONIC KIDNEY DISEASE AND RACE TO THE FRAMINGHAM EQUATION by PAUL E. DRAWZ, MD, MHS Submitted in partial fulfillment of the requirements for the degree of Master

More information

The Whitehall II study originally comprised 10,308 (3413 women) individuals who, at

The Whitehall II study originally comprised 10,308 (3413 women) individuals who, at Supplementary notes on Methods The study originally comprised 10,308 (3413 women) individuals who, at recruitment in 1985/8, were London-based government employees (civil servants) aged 35 to 55 years.

More information

Diabetes and kidney disease.

Diabetes and kidney disease. Diabetes and kidney disease. What are the implications? Can it be prevented? Nice 18 june 2010 Lars G Weiss. M.D. Ph.D. Department of Neprology Central Hospital Karlstad Sweden Diabetic nephropathy vs

More information

ALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)

ALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage

More information

Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease

Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease D. Dallmeier 1, D. Rothenbacher 2, W. Koenig 1, H. Brenner

More information

The Framingham Risk Score (FRS) is widely recommended

The Framingham Risk Score (FRS) is widely recommended C-Reactive Protein Modulates Risk Prediction Based on the Framingham Score Implications for Future Risk Assessment: Results From a Large Cohort Study in Southern Germany Wolfgang Koenig, MD; Hannelore

More information

Numerous epidemiologic studies have shown an association

Numerous epidemiologic studies have shown an association SYMPOSIUM ARTICLE Cardiorenal Risk Factors Barry M. Wall, MD Abstract: The chronic renocardiac syndrome, in which chronic kidney disease (CKD) contributes to impairment of cardiac function or structure,

More information

Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new (MDRD) prediction equation

Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new (MDRD) prediction equation Nephrol Dial Transplant (2002) 17: 1909 1913 Original Article Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new () prediction equation

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Rawshani Aidin, Rawshani Araz, Franzén S, et al. Risk factors,

More information

ISPUB.COM. J Reed III, N Kopyt INTRODUCTION METHODS AND MATERIALS

ISPUB.COM. J Reed III, N Kopyt INTRODUCTION METHODS AND MATERIALS ISPUB.COM The Internet Journal of Nephrology Volume 6 Number 1 Prevalence of Albuminuria in the U.S. Adult Population Over the age of 40: Results from the National Health and Nutrition Examination Survey

More information

CONSIDERABLE STRIDES HAVE

CONSIDERABLE STRIDES HAVE ORIGINAL INVESTIGATION Comparison of Risk Factors for Cardiovascular Mortality in Black and White Adults Mercedes R. Carnethon, PhD; Elizabeth B. Lynch, PhD; Alan R. Dyer, PhD; Donald M. Lloyd-Jones, MD,

More information

Resistant hypertension (RH), that is, blood pressure (BP)

Resistant hypertension (RH), that is, blood pressure (BP) Resistant Hypertension, Time-Updated Blood Pressure Values and Renal Outcome in Type 2 Diabetes Mellitus Francesca Viazzi, MD; Pamela Piscitelli, MD; Antonio Ceriello, MD; Paola Fioretto, MD; Carlo Giorda,

More information

Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.

Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Banks E, Crouch SR, Korda RJ, et al. Absolute risk of cardiovascular

More information

INDEX WORDS: Awareness; chronic kidney disease; Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI); estimated glomerular filtration rate.

INDEX WORDS: Awareness; chronic kidney disease; Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI); estimated glomerular filtration rate. KEEP 2010 Comparison of CKD Awareness in a Screening Population Using the Modification of Diet in Renal Disease (MDRD) Study and CKD Epidemiology Collaboration (CKD-EPI) Equations Manjula Kurella Tamura,

More information

Kidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain)

Kidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain) Kidney and heart: dangerous liaisons Luis M. RUILOPE (Madrid, Spain) Type 2 diabetes and renal disease: impact on cardiovascular outcomes The "heavyweights" of modifiable CVD risk factors Hypertension

More information

Optimal blood pressure targets in chronic kidney disease

Optimal blood pressure targets in chronic kidney disease Optimal blood pressure targets in chronic kidney disease Pr. Michel Burnier Service of Nephrology and Hypertension University Hospital Lausanne Switzerland Evidence-Based Guideline for the Management

More information

CARDIO-RENAL SYNDROME

CARDIO-RENAL SYNDROME CARDIO-RENAL SYNDROME Luis M Ruilope Athens, October 216 DISCLOSURES: ADVISOR/SPEAKER for Astra-Zeneca, Bayer, BMS, Daiichi-Sankyo, Esteve, GSK Janssen, Lacer, Medtronic, MSD, Novartis, Pfizer, Relypsa,

More information

Diagnostic methods 2: receiver operating characteristic (ROC) curves

Diagnostic methods 2: receiver operating characteristic (ROC) curves abc of epidemiology http://www.kidney-international.org & 29 International Society of Nephrology Diagnostic methods 2: receiver operating characteristic (ROC) curves Giovanni Tripepi 1, Kitty J. Jager

More information

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Tangri N, Stevens LA, Griffith J, et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA. 2011;305(15):1553-1559. eequation. Applying the

More information

Hypertension and diabetic nephropathy

Hypertension and diabetic nephropathy Hypertension and diabetic nephropathy Elisabeth R. Mathiesen Professor, Chief Physician, Dr sci Dep. Of Endocrinology Rigshospitalet, University of Copenhagen Denmark Hypertension Brain Eye Heart Kidney

More information

T. Suithichaiyakul Cardiomed Chula

T. Suithichaiyakul Cardiomed Chula T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial

More information

Change in Estimated GFR Associates with Coronary Heart Disease and Mortality

Change in Estimated GFR Associates with Coronary Heart Disease and Mortality Change in Estimated GFR Associates with Coronary Heart Disease and Mortality Kunihiro Matsushita,* Elizabeth Selvin,* Lori D. Bash,* Nora Franceschini, Brad C. Astor,* and Josef Coresh* *Department of

More information

Echocardiography analysis in renal transplant recipients

Echocardiography analysis in renal transplant recipients Original Research Article Echocardiography analysis in renal transplant recipients S.A.K. Noor Mohamed 1*, Edwin Fernando 2, 1 Assistant Professor, 2 Professor Department of Nephrology, Govt. Stanley Medical

More information

LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes

LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes Presented at DSBS seminar on mediation analysis August 18 th Søren Rasmussen, Novo Nordisk. LEADER CV outcome study To determine the effect

More information

Protecting the heart and kidney: implications from the SHARP trial

Protecting the heart and kidney: implications from the SHARP trial Cardiology Update, Davos, 2013: Satellite Symposium Protecting the heart and kidney: implications from the SHARP trial Colin Baigent Professor of Epidemiology CTSU, University of Oxford S1 First CTT cycle:

More information

Guest Speaker Evaluations Viewer Call-In Thanks to our Sponsors: Phone: Fax: Public Health Live T 2 B 2

Guest Speaker Evaluations Viewer Call-In Thanks to our Sponsors: Phone: Fax: Public Health Live T 2 B 2 Public Health Live T 2 B 2 Chronic Kidney Disease in Diabetes: Early Identification and Intervention Guest Speaker Joseph Vassalotti, MD, FASN Chief Medical Officer National Kidney Foundation Thanks to

More information

Chronic Kidney Disease Prevalence and Rate of Diagnosis

Chronic Kidney Disease Prevalence and Rate of Diagnosis The American Journal of Medicine (2007) 120, 981-986 CLINICAL RESEARCH STUDY Chronic Kidney Disease Prevalence and Rate of Diagnosis Timothy P. Ryan, PhD, a James A. Sloand, MD, b Paul C. Winters, MS,

More information

Antihypertensive Trial Design ALLHAT

Antihypertensive Trial Design ALLHAT 1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes

More information

Individual Study Table Referring to Part of Dossier: Volume: Page:

Individual Study Table Referring to Part of Dossier: Volume: Page: Synopsis Abbott Laboratories Name of Study Drug: Paricalcitol Capsules (ABT-358) (Zemplar ) Name of Active Ingredient: Paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For

More information

Comparison of Two Creatinine-Based Estimating Equations in Predicting All-Cause and Cardiovascular Mortality in Patients With Type 2 Diabetes

Comparison of Two Creatinine-Based Estimating Equations in Predicting All-Cause and Cardiovascular Mortality in Patients With Type 2 Diabetes Cardiovascular and Metabolic Risk O R I G I N A L A R T I C L E Comparison of Two Creatinine-Based Estimating Equations in Predicting All-Cause and Cardiovascular Mortality in Patients With Type 2 Diabetes

More information

ACCP Cardiology PRN Journal Club

ACCP Cardiology PRN Journal Club ACCP Cardiology PRN Journal Club Announcements Next journal club Thursday, Dec. 14 th at 3:00 PM EST PACIFY Trial Effects of IV Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients

More information

CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES

CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES C. Liakos, 1 G. Vyssoulis, 1 E. Karpanou, 2 S-M. Kyvelou, 1 V. Tzamou, 1 A. Michaelides, 1 A. Triantafyllou, 1 P. Spanos, 1 C. Stefanadis

More information

The impact of albuminuria and cardiovascular risk factors on renal function Verhave, Jacoba Catharijne

The impact of albuminuria and cardiovascular risk factors on renal function Verhave, Jacoba Catharijne University of Groningen The impact of albuminuria and cardiovascular risk factors on renal function Verhave, Jacoba Catharijne IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's

More information

High-Normal Blood Pressure Progression to Hypertension in the Framingham Heart Study

High-Normal Blood Pressure Progression to Hypertension in the Framingham Heart Study 22 High- Blood Pressure Progression to Hypertension in the Framingham Heart Study Mark Leitschuh, L. Adrienne Cupples, William Kannel, David Gagnon, and Aram Chobanian This study sought to determine if

More information

There is a high prevalence of chronic kidney disease

There is a high prevalence of chronic kidney disease CLINICAL INVESTIGATIONS Kidney Function and Mortality in Octogenarians: Cardiovascular Health Study All Stars Shani Shastri, MD, MPH, MS, a Ronit Katz, DPhil, b Dena E. Rifkin, MD, MS, c Linda F. Fried,

More information

Proteinuria and risk of stroke in patients with hypertension: The Kailuan cohort study

Proteinuria and risk of stroke in patients with hypertension: The Kailuan cohort study Received: 30 October 2017 Revised: 8 February 2018 Accepted: 13 February 2018 DOI: 10.1111/jch.13255 ORIGINAL PAPER Proteinuria and risk of stroke in patients with hypertension: The Kailuan cohort study

More information

( ) , (Donabedian, 1980) We would not choose any treatment with poor outcomes

( ) , (Donabedian, 1980) We would not choose any treatment with poor outcomes ..., 2013 Amgen. 1 ? ( ), (Donabedian, 1980) We would not choose any treatment with poor outcomes 1. :, 2. ( ): 3. :.,,, 4. :, [Biomarkers Definitions Working Group, 2001]., (William M. Bennet, Nefrol

More information

Bariatric Surgery versus Intensive Medical Therapy for Diabetes 3-Year Outcomes

Bariatric Surgery versus Intensive Medical Therapy for Diabetes 3-Year Outcomes The new england journal of medicine original article Bariatric Surgery versus Intensive Medical for Diabetes 3-Year Outcomes Philip R. Schauer, M.D., Deepak L. Bhatt, M.D., M.P.H., John P. Kirwan, Ph.D.,

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Bucholz EM, Butala NM, Ma S, Normand S-LT, Krumholz HM. Life

More information

Although the prevalence and incidence of type 2 diabetes mellitus

Although the prevalence and incidence of type 2 diabetes mellitus n clinical n Validating the Framingham Offspring Study Equations for Predicting Incident Diabetes Mellitus Gregory A. Nichols, PhD; and Jonathan B. Brown, PhD, MPP Background: Investigators from the Framingham

More information

Can modifications of the MDRD formula improve the estimation of glomerular filtration rate in renal allograft recipients?

Can modifications of the MDRD formula improve the estimation of glomerular filtration rate in renal allograft recipients? Nephrol Dial Transplant (7) 22: 361 3615 doi:1.193/ndt/gfm282 Advance Access publication 22 September 7 Original Article Can modifications of the MDRD formula improve the estimation of glomerular filtration

More information

Hypertension is an important global public

Hypertension is an important global public IN THE LITERATURE Blood Pressure Target in Individuals Without Diabetes: What Is the Evidence? Commentary on Verdecchia P, Staessen JA, Angeli F, et al; on behalf of the Cardio-Sis Investigators. Usual

More information

Blood Pressure Monitoring in Chronic Kidney Disease

Blood Pressure Monitoring in Chronic Kidney Disease Blood Pressure Monitoring in Chronic Kidney Disease Aldo J. Peixoto, MD FASN FASH Associate Professor of Medicine (Nephrology), YSM Associate Chief of Medicine, VACT Director of Hypertension, VACT American

More information

Chapter 7. Nynke Halbesma Desiree F. Jansen Martijn W. Heymans Ronald P. Stolk Paul E. de Jong Ron T. Gansevoort. Submitted

Chapter 7. Nynke Halbesma Desiree F. Jansen Martijn W. Heymans Ronald P. Stolk Paul E. de Jong Ron T. Gansevoort. Submitted Development and validation of a General Population Renal Risk Score Nynke Halbesma Desiree F. Jansen Martijn W. Heymans Ronald P. Stolk Paul E. de Jong Ron T. Gansevoort Submitted Abstract There is a need

More information

Beta-blockers for coronary heart disease in chronic kidney disease

Beta-blockers for coronary heart disease in chronic kidney disease Nephrol Dial Transplant (2008) 23: 2274 2279 doi: 10.1093/ndt/gfm950 Advance Access publication 10 January 2008 Original Article Beta-blockers for coronary heart disease in chronic kidney disease Michel

More information

Concept and General Objectives of the Conference: Prognosis Matters. Andrew S. Levey, MD Tufts Medical Center Boston, MA

Concept and General Objectives of the Conference: Prognosis Matters. Andrew S. Levey, MD Tufts Medical Center Boston, MA Concept and General Objectives of the Conference: Prognosis Matters Andrew S. Levey, MD Tufts Medical Center Boston, MA General Objectives Topics to discuss What are the key outcomes of CKD? What progress

More information

Elevation of Serum Creatinine: When to Screen, When to Refer. Bruce F. Culleton, MD, FRCPC; and Jolanta Karpinski, MD, FRCPC

Elevation of Serum Creatinine: When to Screen, When to Refer. Bruce F. Culleton, MD, FRCPC; and Jolanta Karpinski, MD, FRCPC Elevation of Serum Creatinine: When to Screen, When to Refer Bruce F. Culleton, MD, FRCPC; and Jolanta Karpinski, MD, FRCPC Presented at the University of Calgary s CME and Professional Development 2006-2007

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter

More information

Low ALT Levels Independently Associated with 22-Year All-Cause Mortality Among Coronary Heart Disease Patients

Low ALT Levels Independently Associated with 22-Year All-Cause Mortality Among Coronary Heart Disease Patients Low ALT Levels Independently Associated with 22-Year All-Cause Mortality Among Coronary Heart Disease Patients N. Peltz-Sinvani, MD 1,4,R.Klempfner,MD 2,4, E. Ramaty, MD 1,4,B.A.Sela,PhD 3,4,I.Goldenberg,MD

More information

SUPPLEMENTARY DATA. Supplementary Figure S1. Cohort definition flow chart.

SUPPLEMENTARY DATA. Supplementary Figure S1. Cohort definition flow chart. Supplementary Figure S1. Cohort definition flow chart. Supplementary Table S1. Baseline characteristics of study population grouped according to having developed incident CKD during the follow-up or not

More information

Outline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?

Outline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD? CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,

More information

Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with

Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Comparative

More information